Therefore, the aim of this study was to examine PCDHGC3 expression in patient samples of gliomas with different WHO grades and to compare them with clinical parameters to determine whether the PCDHGC3 expression may serve as a prognostic biomarker. Here, PCDHGC3 is linked to central nervous system cancer.